-+ 0.00%
-+ 0.00%
-+ 0.00%

RBC Capital Upgrades Lakefront Biotherapeutics to Outperform, Raises Price Target to $45

Benzinga·09/23/2026 12:51:13
Listen to the news
RBC Capital analyst Brian Abrahams upgrades Lakefront Biotherapeutics (NASDAQ:LKFT) from Sector Perform to Outperform and raises the price target from $26 to $45.